Navigation Links
Application for Listing of Shire Limited Ordinary Shares
Date:5/22/2008

BASINGSTOKE, England and PHILADELPHIA, Pennsylvania, May 23 /PRNewswire-FirstCall/ -- Shire Limited ("Shire") (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that an application has been made to the UK Listing Authority and to the London Stock Exchange for 559,725,147 ordinary shares of 5 pence each in the capital of Shire to be admitted to the Official List and to trading on the London Stock Exchange. Dealings will commence today at 8.00 a.m. (GMT).

As announced on 22 May 2008, the High Court sanctioned the scheme of arrangement proposed between Shire plc and its ordinary shareholders. Under the terms of the scheme, Shire will issue ordinary shares to former holders of ordinary shares in Shire plc on a one-for-one basis. Similarly, Shire plc's American Depositary Shares ("ADSs") will be replaced by Shire's ADSs on a one-for-one basis and NASDAQ dealings will commence today at 9.30 a.m. (EST).

Application has also been made for block listings amounting in aggregate to 6,378,000 ordinary shares of 5 pence each in the capital of Shire to be admitted to the Official List upon issue. The block listings consist of 82,000 shares under the Shire Pharmaceuticals Executive Share Option Scheme, 6,200,000 shares under the Shire Pharmaceuticals Group plc 2000 Executive Share Option Scheme, 14,000 shares under the BioChem Pharma Stock Option Plan and 82,000 shares under the Shire plc Sharesave Plan. Upon issue, these shares shall rank pari passu with all other ordinary shares of Shire.

From today Shire plc will be registered as a private company, wholly owned by Shire, and the listing of Shire plc's ordinary shares of 5 pence each on the Official List will be cancelled as of 8.00 a.m. (GMT) today.

Notes to editors

SHIRE LIMITED

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its busi
'/>"/>

SOURCE Shire Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
3. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
4. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
5. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
8. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
11. Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...ITHERSBURG, Md., Nov. 5 ...financial results for the third quarter ended Sept... million ($0.04 per share) for the three months en...6.8 million ($0.08 per share) in the comparable qu... 30, 2009, GenVec,s net loss was $14.1 million ($0...
(Date:11/5/2009)...N DIEGO, Nov. 5 Imagenet...ay that William Spencer, President and CEO of Imag...the 2nd annual LD MICRO Conference on Thursday, De...Los Angeles. ,, About LD MICRO ,, LD MICRO i...s on finding undervalued companies in the micro-ca...
(Date:11/5/2009)...AHA, Neb., Nov. 5 Transg...unced financial results for the quarter ended Sept...e presented in the tables that follow. ,, Thir...oss of $366,000 or $0.01 per share for the third q...00 or $0.01 per share for the third quarter of 200...
(Date:11/5/2009)...RT WORTH, Texas, Nov. 5 ...nced today that it has entered into a Letter of In...Virtual Health Technologies, Inc. (OTC Bulletin Bo...$1,000,000 in cash and debt, 4,000,000 shares of W... by WNDM on the Veriscrip technology being acquire...
Breaking Biology Technology:GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 2OTCBB-WNDM Announces LOI to Acquire VHGI Assets for $10 Million Cash/Stock 3
...New Flavor Ingredient Achieves ...ber 28, 2008 Senomyx,Inc. (Nasdaq: SNMX ), a lea...gies to discover and develop novel flavor ingredie...dustries, announced today that it has,received a p...ated to a,milestone achieved by Senomyx under the ...
...n Company,s Website -, TUSTIN, Calif., Oct. 28 P... clinical stage biopharmaceutical,company developi...er and,serious virus infections, today announced t...stor Forum 2008 on Thursday, October 30, 2008 at,3...eld at the Palace Hotel,in San Francisco., A live...
...patients with symptomatic Chronic,Obstructive Pulm...ta show reductions in moderate and severe exacerba...on for marketing authorisation in EU and US expect...ation in the US to be initiated, ZURICH, Switzerl...results from a preliminary analysis of four Phase ...
Other Biology Technology:SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 2SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 3Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008 2Nycomed's Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies 2Nycomed's Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies 3
(Date:11/5/2009)...ity have developed synthetic molecules capable of ...V-infected cells, as well as to prostate cancer ce...nal of the American Chemical Society , could lead .... , The molecules called "antibody-recruiting ...uiting molecule targeting prostate cancer" (ARM-P)...
(Date:11/4/2009)...tant to officially endorse green tea as a cancer p... its protective effects, including results of a ne... a journal of the American Association for Cancer ...ncer. , Vassiliki Papadimitrakopoulo, M.D., pro...ead and Neck Medical Oncology at the University of...
(Date:11/4/2009)...ng Beach and Riverside are responsible for a signi... and the true impact of air pollution and ship emi...ed, according to researchers at the University of ...ppears in an online edition of the American Journ...of all childhood asthma cases in Long Beach and si...
Breaking Biology News(10 mins):New synthetic molecules trigger immune response to HIV and prostate cancer 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2USC study finds big air pollution impacts on local communities 2Operation Rescue Announces Keep It Closed Campaign 53523 1Operation Rescue Announces Keep It Closed Campaign 53523 2TWO NEW KLRI PEER REVIEWED PUBLICATIONS 3A Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause 3B Growth Hormone May Increase Risk 4814 1TWO NEW KLRI PEER REVIEWED PUBLICATIONS 3A Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause 3B Growth Hormone May Increase Risk 4814 2TWO NEW KLRI PEER REVIEWED PUBLICATIONS 3A Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause 3B Growth Hormone May Increase Risk 4814 3Switch to digital mammography leads to increased cancer detection rates 53519 1
...cal rainforest interact with each other and their ...archers report in the Oct. 24 issue of the journal... forest dynamics plot of the Pontificia Universida...orest site associated with the Center for Tropical...th Observatory network (CTFS/SIGEO)., It is diffic...
... positive experience. However, by infecting the co... with a Salmonella strain known for causing human...ife Sciences at Arizona State University have shed... broad implications for understanding embryonic de... in humans. Associate Professor Stuart Newfeld and...
...to the mechanisms that underlie a pathological inc...ished by Cell Press in the October 24th issue of t...opment of new strategies for managing this extreme...t failure. , High blood pressure, heart valve dis...kening of the heart muscle, called myocardial hype...
Other Biology News:Diversity of trees in Ecuador's Amazon rainforest defies simple explanation 2Making flies sick reveals new role for growth factors in immunity 2Making flies sick reveals new role for growth factors in immunity 3Making flies sick reveals new role for growth factors in immunity 4Research uncovers new steps on pathway to enlarged heart 2
...urce: Calf thymus Description: Topoisomerase I r...DNA by a transient breakage and rejoining of phosp...ith Topoisomerase I allows molecules to be differe...phoresis (3) . Topoisomerase I is active in the ab...
...A Polymerase I catalyzes the template-directed pol...3 direction. DNA Polymerase I possesses a 3?5 exon... lowers the error rate during DNA replication, and...nables the enzyme to replace nucleotides in the gr...
T7 RNA Polymerase from Invitrogen
T7 RNA Polymerase from Roche Applied Science
Biology Products: